Skip to main content
. 2019 May 3;13(9):1201–1216. doi: 10.1093/ecco-jcc/jjz087

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Pooled risk difference of adverse event [A], serious adverse event [B], infectious adverse event [C] and worsening ulcerative colitis [D] rates, comparing patients treated with active comparator to placebo, stratified by active comparator class.